Journal: Heliyon

Article Title: MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling

doi: 10.1016/j.heliyon.2024.e30409

Figure Lengend Snippet: The relationship between the expression of MAP7 and the clinicopathological features of ovarian carcinoma.

Article Snippet: Subsequently, the cells were incubated overnight at 4 °C with anti-MAP7 antibody (diluted 1:300, HPA029712, Merck, Germany) and anti-CBY1 antibody (1:50, sc-393327, Santa Cruz Biotechnology, USA), and then labeled with Alexa Fluor-488-conjugated secondary antibody (1:400, Mouse, A0428, Beyotime, Shanghai, China) and Alexa Fluor-647-conjugated secondary antibody (1:400, Rabbit, A0468, Beyotime, Shanghai, China) at room temperature.

Techniques: Expressing

Journal: Heliyon

Article Title: MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling

doi: 10.1016/j.heliyon.2024.e30409

Figure Lengend Snippet: (A–G): High expression of MAP7 in ovarian cancer tissues. A. GEPIA data shows MAP7 levels in normal vs. cancerous ovarian tissues. (B–C). GSE27651 and GSE66957 analyses reveal higher MAP7 in ovarian cancer. D. KM-plot indicates worse PFS in high MAP7 expressers (p = 0.031). E. KM-plot links high MAP7 to lower OS (p = 0.048). (F–G). Immunohistochemistry demonstrates MAP7's presence across benign and malignant serous ovarian tumors and various FIGO stages.*p < 0.05 vs Control group.

Article Snippet: Subsequently, the cells were incubated overnight at 4 °C with anti-MAP7 antibody (diluted 1:300, HPA029712, Merck, Germany) and anti-CBY1 antibody (1:50, sc-393327, Santa Cruz Biotechnology, USA), and then labeled with Alexa Fluor-488-conjugated secondary antibody (1:400, Mouse, A0428, Beyotime, Shanghai, China) and Alexa Fluor-647-conjugated secondary antibody (1:400, Rabbit, A0468, Beyotime, Shanghai, China) at room temperature.

Techniques: Expressing, Immunohistochemistry, Control

Journal: Heliyon

Article Title: MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling

doi: 10.1016/j.heliyon.2024.e30409

Figure Lengend Snippet: (A–I): Knockdown of MAP7 inhibits the progression of ovarian cancer cells. (A–B). MAP7 levels across cell lines. RPS18 as internal control for qPCR and GAPDH for Western blotting. (C, E). Knockdown efficiency confirmed. (D, F).Proliferation reduction shown by CCK-8. G. Decreased colony formation. H. Enhanced apoptosis via flow cytometry. I. Reduced migration and invasion in Transwell tests. Each experiment was performed in triplicate and independently repeated three times. (G: scale bar = 5 mm; I: scale bar = 50 μm) *p < 0.05 vs Control group, **p < 0.01vs Control group, ***p < 0.001 vs Control group and****p < 0.0001 vs Control group.

Article Snippet: Subsequently, the cells were incubated overnight at 4 °C with anti-MAP7 antibody (diluted 1:300, HPA029712, Merck, Germany) and anti-CBY1 antibody (1:50, sc-393327, Santa Cruz Biotechnology, USA), and then labeled with Alexa Fluor-488-conjugated secondary antibody (1:400, Mouse, A0428, Beyotime, Shanghai, China) and Alexa Fluor-647-conjugated secondary antibody (1:400, Rabbit, A0468, Beyotime, Shanghai, China) at room temperature.

Techniques: Knockdown, Control, Western Blot, CCK-8 Assay, Flow Cytometry, Migration

Journal: Heliyon

Article Title: MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling

doi: 10.1016/j.heliyon.2024.e30409

Figure Lengend Snippet: (A–H): Overexpression of MAP7 promotes the progression of ovarian cancer cells. (A–B). Confirmed MAP7 overexpression. RPS18 as internal control for qPCR and GAPDH for Western blotting. C. Increased colony formation shown. (D–E).Enhanced proliferation via CCK-8. F. Reduced apoptosis indicated by flow cytometry. (G–H). Greater migration and invasion in Transwell assays. Each experiment was performed in triplicate and independently repeated three times. (C: scale bar = 5 mm; G,H: scale bar = 50 μm) *p < 0.05 vs Control group, **p < 0.01vs Control group, ***p < 0.001 vs Control group and****p < 0.0001 vs Control group.

Article Snippet: Subsequently, the cells were incubated overnight at 4 °C with anti-MAP7 antibody (diluted 1:300, HPA029712, Merck, Germany) and anti-CBY1 antibody (1:50, sc-393327, Santa Cruz Biotechnology, USA), and then labeled with Alexa Fluor-488-conjugated secondary antibody (1:400, Mouse, A0428, Beyotime, Shanghai, China) and Alexa Fluor-647-conjugated secondary antibody (1:400, Rabbit, A0468, Beyotime, Shanghai, China) at room temperature.

Techniques: Over Expression, Control, Western Blot, CCK-8 Assay, Flow Cytometry, Migration

Journal: Heliyon

Article Title: MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling

doi: 10.1016/j.heliyon.2024.e30409

Figure Lengend Snippet: (A–F): MAP7 may promote epithelial-mesenchymal transition (EMT) in ovarian cancer cells by activating the Wnt/β-catenin pathway. A. MAP7 expression linked to EMT. B. MAP7's role in cytoskeletal organization shown by immunofluorescence. (C–D). MAP7's promotion of EMT. (E–F). Activation of the Wnt/β-catenin pathway by MAP7. Each experiment was performed in triplicate and independently repeated three times. (B: scale bar = 20 μm).

Article Snippet: Subsequently, the cells were incubated overnight at 4 °C with anti-MAP7 antibody (diluted 1:300, HPA029712, Merck, Germany) and anti-CBY1 antibody (1:50, sc-393327, Santa Cruz Biotechnology, USA), and then labeled with Alexa Fluor-488-conjugated secondary antibody (1:400, Mouse, A0428, Beyotime, Shanghai, China) and Alexa Fluor-647-conjugated secondary antibody (1:400, Rabbit, A0468, Beyotime, Shanghai, China) at room temperature.

Techniques: Expressing, Immunofluorescence, Activation Assay

Journal: Heliyon

Article Title: MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling

doi: 10.1016/j.heliyon.2024.e30409

Figure Lengend Snippet: (A–K): The expression of MAP7 is associated with cisplatin resistance in ovarian cancer cells. A. RNA-seq submission schematic. B. A2780-DDP cell line development flowchart. C. Rising MAP7 levels with increased resistance. D. CCK-8 shows reduced A2780-DDP proliferation post-MAP7 knockdown. E. Lowered IC50 reflects decreased resistance. F. Enhanced A2780-DDP migration and invasion in Transwell assays. G. Cytoskeletal changes via immunofluorescence. H. Western blots reveal EMT activation. I. Wnt/β-catenin/C-myc pathway upregulation drives EMT and resistance. Each experiment was performed in triplicate and independently repeated three times. (H: scale bar = 50 μm; I: scale bar = 20 μm) ns, not significant, *p < 0.05 vs Control group, **p < 0.01vs Control group, ***p < 0.001 vs Control group and****p < 0.0001 vs Control group.

Article Snippet: Subsequently, the cells were incubated overnight at 4 °C with anti-MAP7 antibody (diluted 1:300, HPA029712, Merck, Germany) and anti-CBY1 antibody (1:50, sc-393327, Santa Cruz Biotechnology, USA), and then labeled with Alexa Fluor-488-conjugated secondary antibody (1:400, Mouse, A0428, Beyotime, Shanghai, China) and Alexa Fluor-647-conjugated secondary antibody (1:400, Rabbit, A0468, Beyotime, Shanghai, China) at room temperature.

Techniques: Expressing, RNA Sequencing, CCK-8 Assay, Knockdown, Migration, Immunofluorescence, Western Blot, Activation Assay, Control

Journal: Heliyon

Article Title: MAP7 drives EMT and cisplatin resistance in ovarian cancer via wnt/β-catenin signaling

doi: 10.1016/j.heliyon.2024.e30409

Figure Lengend Snippet: (A–D): CBY1 may serve as a target for the action of MAP7 within the nucleus of A2780-DDP cells. A: Elevated nuclear MAP7 in A2780-DDP. The white arrow shows the expression of MAP7 in the nucleus. B: Western blot highlights nuclear MAP7 and β-catenin translocation, GAPDH was used as a positive reference for cytoplasmic localization and H3 was used as a positive reference for nuclear localization. C: BioGRID database shows MAP7-CBY1 interaction. D: COIP reveals interactions between MAP7, CBY1, β-catenin. E. Immunofluorescence staining showing the co-localization of MAP7 and CBY1. Each experiment was performed in triplicate and independently repeated three times. (A, E: scale bar = 20 μm) ****p < 0.0001 vs Control group.

Article Snippet: Subsequently, the cells were incubated overnight at 4 °C with anti-MAP7 antibody (diluted 1:300, HPA029712, Merck, Germany) and anti-CBY1 antibody (1:50, sc-393327, Santa Cruz Biotechnology, USA), and then labeled with Alexa Fluor-488-conjugated secondary antibody (1:400, Mouse, A0428, Beyotime, Shanghai, China) and Alexa Fluor-647-conjugated secondary antibody (1:400, Rabbit, A0468, Beyotime, Shanghai, China) at room temperature.

Techniques: Expressing, Western Blot, Translocation Assay, Immunofluorescence, Staining, Control